Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06624085
- Locations
- 🇺🇸
Saddleback Memorial Medical Center, Laguna Hills, California, United States
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 750
- Registration Number
- NCT06607185
- Locations
- 🇨🇳
Hsin-Chu Hospital, Hsin-chu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸START Midwest, Grand Rapids, Michigan, United States
The Efficacy and Safety of Benmelstobart for GC/EGC
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06603974
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
UCLA, Santa Monica, California, United States
🇺🇸City of Hope Medical Group, South Pasadena, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06547385
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 65
- Registration Number
- NCT06540261
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Kurashiki Central Hospital, Kurashiki, Okayama, Japan
🇯🇵Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06538207
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06532344
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.